


Preferred COX-2 inhibitors that may be used in the present invention include, but are not limited to:

C1)

5



JTE-522, 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide;

C2)

10

5-chloro-3-(4-(methylsulfonyl)phenyl)-2-(methyl-5-pyridinyl)pyridine;


C3)

15

2-(3,5-difluorophenyl)-3-4-(methylsulfonyl)phenyl)-2-cyclopenten-1-one;


C4)

20



4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide;


C5)



rofecoxib, 4-(4-(methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone;

5

C6)



4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide;


10

C7)

N-[[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]propanamide;


15

C8)




4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazole-1-yl]benzenesulfonamide;

C9)




;

5 . C10)




;

C11)



10 6-[(5-(4-chlorobenzoyl)-1,4-dimethyl-1H-
pyrrol-2-yl)methyl]-3(2H)-pyridazinone;

C12)



N-(4-nitro-2-phenoxyphenyl)methanesulfonamide;